Compare Citius Pharmaceuticals Inc (CTXR) vs FMC Corp (FMC) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

FMC Corporation (FMC) trades at $10.91 with no change in the latest session. The agricultural sciences company shows mixed signals with a bearish technical outlook but positive analyst sentiment (47.6% buy ratings). Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submissions for new herbicide technology. However, fundamental challenges persist with negative net income margin of -72.93% and declining revenue from $5.8B in 2022 to $3.47B in 2025.

The stock presents a turnaround opportunity with attractive valuation metrics (P/S 0.4x, P/B 0.75x) and significant upside to the $16 consensus price target. Key risks include continued revenue declines, negative cash flow from operations, and high debt levels. The company's strategic moves to reduce debt and advance new products could drive recovery if execution improves.